{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:04:07Z","timestamp":1790391847702,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3476,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1038\/sj.ki.5000432","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T17:56:46Z","timestamp":1146679006000},"page":"2124-2130","source":"Crossref","is-referenced-by-count":168,"title":["Vasopressin receptor antagonists"],"prefix":"10.1016","volume":"69","author":[{"given":"A.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Verbalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5000432_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1152\/physrev.00024.2001","article-title":"Aquaporins in the kidney: from molecules to medicine","volume":"82","author":"Nielsen","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1038\/sj.ki.5000432_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-144-3-200602070-00007","article-title":"Nephrogenic diabetes insipidus","volume":"144","author":"Sands","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5000432_bb0020","series-title":"Vasopressin. Third International Vasopressin Conference","first-page":"321","article-title":"Antidiuretic hormone antagonism in humans: are there predictors?","author":"Kinter","year":"1991"},{"key":"10.1038\/sj.ki.5000432_bb0025","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116881","article-title":"Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men","volume":"92","author":"Ohnishi","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1038\/sj.ki.5000432_bb0030","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198810203191606","article-title":"Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1)","volume":"319","author":"Schrier","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5000432_bb0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM198810273191705","article-title":"Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2)","volume":"319","author":"Schrier","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5000432_bb0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-96-4-413","article-title":"Role of vasopressin in abnormal water excretion in cirrhotic patients","volume":"96","author":"Bichet","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5000432_bb0045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/jpet.105.095554","article-title":"Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor","volume":"316","author":"Macion-Dazard","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/sj.ki.5000432_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1067\/mlc.2001.116025","article-title":"Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985","volume":"138","author":"Decaux","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1038\/sj.ki.5000432_bb0055","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","article-title":"Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites","volume":"36","author":"Guyader","year":"2002","journal-title":"Hepatology"},{"key":"10.1038\/sj.ki.5000432_bb0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","article-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial","volume":"124","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1038\/sj.ki.5000432_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"key":"10.1038\/sj.ki.5000432_bb0070","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ki.1995.287","article-title":"Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans","volume":"48","author":"Shimizu","year":"1995","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5000432_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0009-9236(98)90107-2","article-title":"Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis","volume":"63","author":"Inoue","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/sj.ki.5000432_bb0080","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1210\/jcem.82.4.3900","article-title":"Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"82","author":"Saito","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/sj.ki.5000432_bb0085","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000432_bb0090","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV in CHF)","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1038\/sj.ki.5000432_bb0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J Card Fail"},{"key":"10.1038\/sj.ki.5000432_bb0100","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000432_bb0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9343(01)00678-7","article-title":"Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide","volume":"110","author":"Decaux","year":"2001","journal-title":"Am J Med"},{"key":"10.1038\/sj.ki.5000432_bb0110","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogue","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5000432_bb0115","series-title":"National Kidney Foundation Primer on Kidney Diseases","first-page":"66","article-title":"Hyponatremia and hypo-osmolar disorders","author":"Verbalis","year":"2005"},{"key":"10.1038\/sj.ki.5000432_bb0120","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5000432_bb0125","doi-asserted-by":"crossref","first-page":"18F","DOI":"10.1016\/S0002-9149(02)03336-2","article-title":"Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations","volume":"91","author":"Klein","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1038\/sj.ki.5000432_bb0130","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"68","author":"Torres","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5000432_bb0135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1038\/sj.ki.5000432_bb0140","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1681\/ASN.2005040371","article-title":"Molecular biology of hereditary diabetes insipidus","volume":"16","author":"Fujiwara","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5000432_bb0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for x-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815514427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815514427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T20:27:42Z","timestamp":1547670462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815514427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0085253815514427"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5000432","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}